Publication: Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.
| dc.contributor.author | Ryan, Pablo | |
| dc.contributor.author | Valencia, Jorge | |
| dc.contributor.author | Pérez-García, Felipe | |
| dc.contributor.author | Quero-Delgado, Marta | |
| dc.contributor.author | Cuevas, Guillermo | |
| dc.contributor.author | Manzano, Samuel | |
| dc.contributor.author | Estévez, Samuel | |
| dc.contributor.author | Martinez, Isidoro | |
| dc.contributor.author | Sepulveda-Crespo, Daniel | |
| dc.contributor.author | Resino, Salvador | |
| dc.contributor.funder | Gilead Sciences (Spain) | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | AbbVie | |
| dc.contributor.funder | Asociación Española para el Estudio del Hígado | |
| dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | |
| dc.date.accessioned | 2026-06-15T11:58:38Z | |
| dc.date.available | 2026-06-15T11:58:38Z | |
| dc.date.issued | 2025-07 | |
| dc.description.abstract | Background: Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals.AIMTo evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23. Methods: At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values). Results: TSAmong 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used (aIRR: 7.3; 95% CI: 2.7-12.7) and active (aIRR: 14.7; 95% CI: 6.7-32.1)), European origin (vs non-European; aIRR: 5.8; 95% CI: 2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups. Conclusion: At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations. | |
| dc.description.peerreviewed | Sí | |
| dc.description.sponsorship | This work was funded by a research grant from Gilead Science (IN-ES-380-6205, IN-ES-987-5391, GLD19_0096 to PR and GLD20_0144 to SR) and Instituto de Salud Carlos III (ISCII; grant numbers PI20CIII/00004 to SR, PI23CIII/00018 to DSC and IM, and PI19CIII/00009 to IM). It also received funding from AbbVie, the Asociación Española para Estudio del Higado (AEEH), and the Madrid Positivo Association. The study was also funded by the CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (grant numbers CB21/13/00044 to SR). DSC is a ‘Miguel Servet’ researcher from ISCIII (grant number CP23CIII/00004). The funding sources played no role in the study's design, collection, analysis, interpretation of the data, or manuscript writing. | |
| dc.format.number | 29 | |
| dc.format.page | 2500150 | |
| dc.format.volume | 30 | |
| dc.identifier.citation | Ryan Pablo, Valencia Jorge, Pérez-García Felipe, Quero-Delgado Marta, Cuevas Guillermo, Manzano Samuel, Estévez Samuel, Martínez Isidoro, Sepúlveda-Crespo Daniel, Resino Salvador. Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023. Euro Surveill. 2025;30(29):pii=2500150. https://doi.org/10.2807/1560-7917.ES.2025.30.29.2500150. | |
| dc.identifier.doi | 10.2807/1560-7917.ES.2025.30.29.2500150 | |
| dc.identifier.journal | Europe's journal on infectious disease surveillance, epidemiology, prevention and control (Eurosurveillance) | |
| dc.identifier.pubmedID | 40709474 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/27532 | |
| dc.language.iso | eng | |
| dc.publisher | European Centre for Disease Prevention and Control (ECDC) | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Gilead Science//IN-ES-380-6205/// | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Gilead Science//IN-ES-987-5391/// | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Gilead Science//GLD19_0096/// | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Gilead Science//GLD20_0144/// | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI20CIII%2F00004//Infecciones agudas%2Frecientes y reinfecciones por VHC en hombres que tienen sexo con hombres con y sin VIH/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI23CIII%2F00018//Nanosistemas dentríticos aplicados al diagnóstico de infecciones virales/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI19CIII%2F00009//Desarrollo de un ensayo de diagnóstico rápido para el cribado de la infección activa del virus de la hepatitis C basado en la detección del core/VHCAgc | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII-CIBER-Ministerio de Ciencia e Innovación-Unión Europea–NextGenerationEU//CB21%2F13%2F00044/ES// | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/CP23CIII%2F00004/ES// | |
| dc.relation.publisherversion | https://doi.org/10.2807/1560-7917.ES.2025.30.29.2500150 | |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología (CNM) | |
| dc.repisalud.institucion | ISCIII | |
| dc.repisalud.institute | IIS::IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid) | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Hepatitis C | |
| dc.subject | Spain | |
| dc.subject | Injection drug use | |
| dc.subject | Migrant populations | |
| dc.subject | Mobile screening unit | |
| dc.subject | Risk factors | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Antiviral Agents | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Hepacivirus | |
| dc.subject.mesh | Hepatitis C Antibodies | |
| dc.subject.mesh | Hepatitis C | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Mass Screening | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Prevalence | |
| dc.subject.mesh | Risk Factors | |
| dc.subject.mesh | Spain | |
| dc.subject.mesh | Transients and Migrants | |
| dc.subject.mesh | Young Adult | |
| dc.title | Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 91fafbb0-4d25-4be8-969e-5b9941af71ca | |
| relation.isAuthorOfPublication | 3ef39da6-a7d1-43fc-8309-3429a6ea9918 | |
| relation.isAuthorOfPublication | 89b17350-14e3-4dfd-b797-6ee6ca5363b8 | |
| relation.isAuthorOfPublication.latestForDiscovery | 89b17350-14e3-4dfd-b797-6ee6ca5363b8 | |
| relation.isFunderOfPublication | e30731f7-32c2-43af-b658-fe28964bc958 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | ffb8e2d3-a3e4-4345-ade9-736e37d36399 | |
| relation.isFunderOfPublication | d9ab2217-c797-4f04-aac0-470082905377 | |
| relation.isFunderOfPublication | 0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72 | |
| relation.isFunderOfPublication.latestForDiscovery | e30731f7-32c2-43af-b658-fe28964bc958 | |
| relation.isPublisherOfPublication | 844b1441-479c-4219-87e5-efc493160a02 | |
| relation.isPublisherOfPublication.latestForDiscovery | 844b1441-479c-4219-87e5-efc493160a02 |


